CHMP recommends Leo Pharma's tralokinumab for approval in atopic dermatitis
The EMA's Committee for Medicinal Products for Human Use (CHMP) recommends the approval of Leo Pharma's new eczema treatment tralokinumab within the EU. There is hope the drug will take the company to new heights.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Almost five years after acquiring tralokinumab from Astrazeneca, Leo Pharma is at the cusp of getting approval for the drug on the European market.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma's board now has one person less
For subscribers
